Epigenetic Drug Interventions in Breast Cancer: A Narrative Review of Current Research and Future Directions
Breast cancer is a life-threatening disease known for its extensive molecular heterogeneity. The study of the breast cancer epigenome has revealed potential avenues for improving breast cancer treatment risk stratification, early detection, and treatment. With renewed interest in epigenetic-modifyi...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
HH Publisher
2024-09-01
|
| Series: | Progress in Microbes and Molecular Biology |
| Online Access: | https://journals.hh-publisher.com/index.php/pmmb/article/view/1055 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832541394041831424 |
|---|---|
| author | Sarah Bibi Mungly Evelyn Priya Peter Ling-Wei Hii Chun-Wai Mai Felicia Fei-Lei Chung |
| author_facet | Sarah Bibi Mungly Evelyn Priya Peter Ling-Wei Hii Chun-Wai Mai Felicia Fei-Lei Chung |
| author_sort | Sarah Bibi Mungly |
| collection | DOAJ |
| description |
Breast cancer is a life-threatening disease known for its extensive molecular heterogeneity. The study of the breast cancer epigenome has revealed potential avenues for improving breast cancer treatment risk stratification, early detection, and treatment. With renewed interest in epigenetic-modifying pharmaceutical agents, namely DNA methyltransferase inhibitors (DNMTi), histone deacetylase inhibitors (HDACi), bromodomain and extra-terminal inhibitors (BETi), and enhancer of zeste homolog 2 inhibitors (EZH2i), there have been extensive preclinical and clinical studies to evaluate the safety and efficacy of these agents as potential treatments for breast cancer. In this review, we summarise and present the preclinical and clinical evidence for epigenetic drugs in treating breast cancer. We review the challenges associated with the translation of these findings into improved patient outcomes, namely the optimisation of dosage and treatment regimens, and the emergence of resistance. These challenges have been widely recognised in the field and are of utmost importance for the successful implementation of personalised medicine. While there is strong evidence that epigenetic alterations, consisting of changes in DNA methylation, histone modifications, and non-coding RNAs, play a crucial role in breast cancer initiation and development, additional research is warranted to elucidate the safety profile of long-term interventions involving epigenetic drugs and to validate the role of epigenetic markers in disease diagnosis, prognosis, and personalised treatment.
|
| format | Article |
| id | doaj-art-34528669936b49ea8f8bae1e6ad32a1c |
| institution | Kabale University |
| issn | 2637-1049 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | HH Publisher |
| record_format | Article |
| series | Progress in Microbes and Molecular Biology |
| spelling | doaj-art-34528669936b49ea8f8bae1e6ad32a1c2025-02-04T08:39:37ZengHH PublisherProgress in Microbes and Molecular Biology2637-10492024-09-017110.36877/pmmb.a0000448Epigenetic Drug Interventions in Breast Cancer: A Narrative Review of Current Research and Future DirectionsSarah Bibi MunglyEvelyn Priya PeterLing-Wei HiiChun-Wai MaiFelicia Fei-Lei Chung Breast cancer is a life-threatening disease known for its extensive molecular heterogeneity. The study of the breast cancer epigenome has revealed potential avenues for improving breast cancer treatment risk stratification, early detection, and treatment. With renewed interest in epigenetic-modifying pharmaceutical agents, namely DNA methyltransferase inhibitors (DNMTi), histone deacetylase inhibitors (HDACi), bromodomain and extra-terminal inhibitors (BETi), and enhancer of zeste homolog 2 inhibitors (EZH2i), there have been extensive preclinical and clinical studies to evaluate the safety and efficacy of these agents as potential treatments for breast cancer. In this review, we summarise and present the preclinical and clinical evidence for epigenetic drugs in treating breast cancer. We review the challenges associated with the translation of these findings into improved patient outcomes, namely the optimisation of dosage and treatment regimens, and the emergence of resistance. These challenges have been widely recognised in the field and are of utmost importance for the successful implementation of personalised medicine. While there is strong evidence that epigenetic alterations, consisting of changes in DNA methylation, histone modifications, and non-coding RNAs, play a crucial role in breast cancer initiation and development, additional research is warranted to elucidate the safety profile of long-term interventions involving epigenetic drugs and to validate the role of epigenetic markers in disease diagnosis, prognosis, and personalised treatment. https://journals.hh-publisher.com/index.php/pmmb/article/view/1055 |
| spellingShingle | Sarah Bibi Mungly Evelyn Priya Peter Ling-Wei Hii Chun-Wai Mai Felicia Fei-Lei Chung Epigenetic Drug Interventions in Breast Cancer: A Narrative Review of Current Research and Future Directions Progress in Microbes and Molecular Biology |
| title | Epigenetic Drug Interventions in Breast Cancer: A Narrative Review of Current Research and Future Directions |
| title_full | Epigenetic Drug Interventions in Breast Cancer: A Narrative Review of Current Research and Future Directions |
| title_fullStr | Epigenetic Drug Interventions in Breast Cancer: A Narrative Review of Current Research and Future Directions |
| title_full_unstemmed | Epigenetic Drug Interventions in Breast Cancer: A Narrative Review of Current Research and Future Directions |
| title_short | Epigenetic Drug Interventions in Breast Cancer: A Narrative Review of Current Research and Future Directions |
| title_sort | epigenetic drug interventions in breast cancer a narrative review of current research and future directions |
| url | https://journals.hh-publisher.com/index.php/pmmb/article/view/1055 |
| work_keys_str_mv | AT sarahbibimungly epigeneticdruginterventionsinbreastcanceranarrativereviewofcurrentresearchandfuturedirections AT evelynpriyapeter epigeneticdruginterventionsinbreastcanceranarrativereviewofcurrentresearchandfuturedirections AT lingweihii epigeneticdruginterventionsinbreastcanceranarrativereviewofcurrentresearchandfuturedirections AT chunwaimai epigeneticdruginterventionsinbreastcanceranarrativereviewofcurrentresearchandfuturedirections AT feliciafeileichung epigeneticdruginterventionsinbreastcanceranarrativereviewofcurrentresearchandfuturedirections |